Evidence map›Paper›PMID 32775170›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2020

Tandem-Mass-Tag Based Proteomic Analysis Facilitates Analyzing Critical Factors of Porous Silicon Nanoparticles in Determining Their Biological Responses under Diseased Condition.

Yunzhan Li, Zehua Liu, Li Li, Wenhua Lian, Yaohui He, Elbadry Khalil, Ermei Mäkilä, Wenzhong Zhang, Giulia Torrieri, Xueyan Liu and 9 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Autologous Skin Fibroblast-Based PLGA Nanoparticles for Treating Multiorgan Fibrosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022
    Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 2 countries.

Yunzhan LiState Key Laboratory of Cellular Stress Biology Innovation Center for Cell Signaling Network School of Life Sciences Xiamen University Fujian 361101 China.
Zehua LiuDrug Research program Division of Pharmaceutical Chemistry and Technology Drug Research Program Faculty of Pharmacy University of Helsinki Helsinki FI-00014 Finland.
Li LiState Key Laboratory of Cellular Stress Biology Innovation Center for Cell Signaling Network School of Life Sciences Xiamen University Fujian 361101 China.
Wenhua LianState Key Laboratory of Cellular Stress Biology Innovation Center for Cell Signaling Network School of Life Sciences Xiamen University Fujian 361101 China.
Yaohui HeSchool of Pharmaceutical Sciences Xiamen University Fujian 361101 China.
Elbadry KhalilDrug Research program Division of Pharmaceutical Chemistry and Technology Drug Research Program Faculty of Pharmacy University of Helsinki Helsinki FI-00014 Finland.
Ermei MäkiläLaboratory of Industrial Physics Department of Physics University of Turku Turku FI-20014 Finland.
Wenzhong ZhangDepartment of Chemistry University of Helsinki Helsinki FI-00014 Finland.
Giulia TorrieriDrug Research program Division of Pharmaceutical Chemistry and Technology Drug Research Program Faculty of Pharmacy University of Helsinki Helsinki FI-00014 Finland.
Xueyan LiuState Key Laboratory of Cellular Stress Biology Innovation Center for Cell Signaling Network School of Life Sciences Xiamen University Fujian 361101 China.
Jingyi SuState Key Laboratory of Cellular Stress Biology Innovation Center for Cell Signaling Network School of Life Sciences Xiamen University Fujian 361101 China.
Yuanming XiuState Key Laboratory of Cellular Stress Biology Innovation Center for Cell Signaling Network School of Life Sciences Xiamen University Fujian 361101 China.
Flavia FontanaDrug Research program Division of Pharmaceutical Chemistry and Technology Drug Research Program Faculty of Pharmacy University of Helsinki Helsinki FI-00014 Finland.
Jarno SalonenLaboratory of Industrial Physics Department of Physics University of Turku Turku FI-20014 Finland.
Jouni HirvonenDrug Research program Division of Pharmaceutical Chemistry and Technology Drug Research Program Faculty of Pharmacy University of Helsinki Helsinki FI-00014 Finland.
Wen LiuSchool of Pharmaceutical Sciences Xiamen University Fujian 361101 China.
Hongbo ZhangPharmaceutical Sciences Laboratory and Turku Bioscience Centre Abo Akademi University Turku FI-20520 Finland.
Hélder A SantosDrug Research program Division of Pharmaceutical Chemistry and Technology Drug Research Program Faculty of Pharmacy University of Helsinki Helsinki FI-00014 Finland.ORCID https://orcid.org/0000-0001-7850-6309
Xianming DengState Key Laboratory of Cellular Stress Biology Innovation Center for Cell Signaling Network School of Life Sciences Xiamen University Fujian 361101 China.
Xiamen University · CNUniversity of Helsinki · FIUniversity of Turku · FIÅbo Akademi University · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The analysis of nanoparticles' biocompatibility and immunogenicity is mostly performed under a healthy condition. However, more clinically relevant evaluation conducted under pathological condition is less known. Here, the immunogenicity and bio-nano interactions of porous silicon nanoparticles (PSi NPs) are evaluated in an acute liver inflammation mice model. Interestingly, a new mechanism in which PSi NPs can remit the hepatocellular damage and inflammation activation in a surface dependent manner through protein corona formation, which perturbs the inflammation by capturing the pro-inflammatory signaling proteins that are inordinately excreted or exposed under pathological condition, is found. This signal sequestration further attenuates the nuclear factor

Indexed as

acute liver inflammationimmunogenicityporous siliconprotein coronaR‐language

Identifiers

PMID32775170
PMCPMC7404168
OpenAlexW3037070482

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.